The required frozen transport of upcoming Covid-19 vaccines, developed by Pfizer/BioNTech and Moderna, are posing a problem for effective distribution.
Pfizer have stated that their vaccine requires storage and transportation at -70 degrees celsius. Below this, the novel vaccine structure is at risk of degradation.
Such ultra cold conditions are not commonplace in the medical and transport industry.
This is where Moderna may have found an edge. The American biotech company claims that its vaccine can withstand far warmer conditions, remaining effective at -20 degrees celsius for a span of 6 months, 7 degrees celsius for 30 days, and room temperature for 24 hours.
Such temperature resilience will surely save millions in distribution and storage.